Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide-associated hepatotoxicity.

J W Goldberg, M D Lidsky

    Southern Medical Journal
    |February 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Cyclophosphamide is an effective rheumatic disease treatment. However, this study reports two cases of liver dysfunction in patients taking oral cyclophosphamide, highlighting a potential risk.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Antibodies to phosphatidylserine/prothrombin complex in suspected antiphospholipid syndrome in the absence of antibodies to cardiolipin or Beta-2-glycoprotein I.

    Lupus·2013
    Same author

    A diabetic man with persistent joint pain and infection.

    Hospital practice (1995)·1997
    Same author

    Recurrent disseminated infection with Mycobacterium avium complex identified in tissues by molecular analysis.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1996
    Same author

    Articular histoplasmosis.

    The Journal of rheumatology·1992
    Same author

    A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease.

    The Annals of pharmacotherapy·1992
    Same author

    Rapid onset of quadriplegia from a panspinal epidural abscess.

    Spine·1991
    Same journal

    The Five Essential Concepts of Developmental Medicine: A Medical Paradigm for People with Developmental Disabilities.

    Southern medical journal·2026
    Same journal

    α-Gal Syndrome in the South: Why We Need Treatment Trials, Not Just Tick Prevention.

    Southern medical journal·2026
    Same journal

    Association between Main Pancreatic Duct Size, Comorbidities, and Fistula Formation after Whipple Procedure for Pancreatic Cancer.

    Southern medical journal·2026
    Same journal

    Impact of Temperature Variation on Patients with Acute Severe Asthma.

    Southern medical journal·2026
    Same journal

    Assessing the Accuracy and Reliability of ChatGPT-4 to Answer Clinical EHR Messages in Sports Medicine.

    Southern medical journal·2026
    Same journal

    Diagnostic Utility and Clinical Implications of Inpatient Fecal Occult Blood Testing.

    Southern medical journal·2026
    See all related articles

    Area of Science:

    • Rheumatology
    • Hepatology
    • Pharmacology

    Background:

    • Cyclophosphamide is a widely used alkylating agent for treating various rheumatic diseases.
    • The drug undergoes primary activation in the liver.
    • Hepatic toxicity is considered a rare side effect of cyclophosphamide therapy.

    Observation:

    • Two distinct cases of hepatic dysfunction were observed in patients with systemic rheumatic diseases.
    • These episodes occurred following the administration of oral cyclophosphamide.
    • The patients' underlying rheumatic conditions were being managed with cyclophosphamide.

    Findings:

    • The study documents two instances of liver injury linked to oral cyclophosphamide.
    • This contrasts with the generally low incidence of reported hepatic toxicity for this drug.

    Related Experiment Videos

  • The observed hepatic dysfunction suggests a potential, albeit infrequent, adverse effect on liver function.

    • Implications:

    • Clinicians should be aware of the potential for hepatic dysfunction when prescribing oral cyclophosphamide for rheumatic conditions.
    • Monitoring liver function may be warranted in patients receiving this therapy.
    • Further investigation into the mechanisms and risk factors for cyclophosphamide-induced hepatotoxicity is needed.